Key points are not available for this paper at this time.
Abstract Sonodynamic therapy (SDT) offers a remarkable non‐invasive ultrasound (US) treatment by activating sonosensitizer and generating reactive oxygen species (ROS) to inhibit tumor growth. The development of multifunctional, biocompatible, and highly effective sonosensitizers remains a current priority for SDT. Herein, the first report that Mn(II) ions chelated Gd‐TCPP (GMT) nanosheets (NSs) are synthesized via a simple reflux method and encapsulated with pluronic F‐127 to form novel sonosensitizers (GMTF). The GMTF NSs produce a high yield of ROS under US irradiation due to the decreased highest occupied molecular orbital−lowest unoccupied molecular orbital gap energy (2.7–1.28 eV). Moreover, Mn(II) ions endow GMTF with a fascinating Fenton‐like activity to produce hydroxyl radicals in support of chemodynamic therapy (CDT). It is also effectively used in magnetic resonance imaging (MRI) with high relaxation rate ( r 1 : 4.401 mM −1 s −1 ) to track the accumulation of NSs in tumors. In vivo results indicate that the SDT and CDT in combination with programmed cell death protein 1 antibody (anti‐PD‐1) show effective metastasis prevention effects, and 70% of the mice in the GMTF + US + anti‐PD‐1 group survived for 60 days. In conclusion, this study develops a sonosensitizer with promising potential for utilizing both MRI‐guided SDT and CDT strategies.
Hang et al. (2023) studied this question.